Overactive Bladder: Clinical Trials

8 trials for Overactive Bladder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Terminated 8
Phase 21Terminated 1

Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2
Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder
Phase 3TerminatedIpsen2582016-07-082022-09-28
Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
Succinate of Solifenacin, Placebo of Succinate of Solifenacin - Overactive Bladder
Phase 3TerminatedCenter Eugene Marquis42016-07-012018-01-19
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder
Phase 3TerminatedIpsen2272016-03-012022-09-28
Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder
Bryophyllum - Overactive Bladder, Urge Urinary Incontinence
Phase 2 / Phase 3TerminatedUniversity of Zurich92014-05-012017-10-26
Over Active Bladder Instillation Study - Botox
Botox Instillation, DMSO Instillation - Overactive Bladder, Urinary Urge Incontinence
Phase 3TerminatedMayo Clinic252008-04-012014-07-11
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
botulinum toxin Type A, Normal Saline (Placebo) - Overactive Bladder
Phase 3TerminatedAllergan412007-06-012014-01-24
Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder
Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification - Overactive Bladder
Phase 3TerminatedLahey Clinic122006-09-012018-04-04
Local Anesthetic Treatments for Overactive Bladder
alkalinized xylocaine, placebo - Overactive Bladder
Phase 3TerminatedFrank Tu222006-03-012020-03-06

Narrower conditions

Urinary Bladder, Overactive (8)  ·  Urinary Incontinence (4)  ·  Urinary Incontinence, Urge (2)

Broader conditions

Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Lower Urinary Tract Symptoms (8)  ·  Male Urogenital Diseases (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Signs and Symptoms (8)  ·  Urinary Bladder Diseases (8)  ·  Urogenital Diseases (8)  ·  Urologic Diseases (8)  ·  Urological Manifestations (8)  ·  Urination Disorders (5)  ·  Urinary Incontinence (1)

Interventions

Botulinum Toxins, Type A (4)  ·  Saline Solution (2)  ·  abobotulinumtoxinA (2)  ·  Dimethyl Sulfoxide (1)  ·  Solifenacin Succinate (1)

Sponsors

Ipsen (2)  ·  Allergan (1)  ·  Center Eugene Marquis (1)  ·  Frank Tu (1)  ·  Lahey Clinic (1)  ·  Mayo Clinic (1)  ·  University of Zurich (1)

Countries

United States (5)  ·  Australia (2)  ·  Canada (2)  ·  France (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)  ·  Colombia (1)  ·  Czechia (1)  ·  Germany (1)  ·  India (1)  ·  Israel (1)  ·  Italy (1)  ·  Lithuania (1)

Top investigators

Frank F. Tu, MD, MPH (1)  ·  John T Stoffel, M.D. (1)  ·  Renaud de Crevoisier, MD (1)  ·  Steven P Petrou, MD (1)

Results publications

PMID 35400537, PMID 23218404

NIH funding

2015 (2), 2014 (1)